Your startup attorney did their job. The SAFE agreement you're holding is a legal document — it's enforceable, it reflects current market terms, and your lawyer didn't commit malpractice. That's not what we're talking about.
What we're talking about is the gap between "this document is legal" and "this document is founder-friendly." Most startup lawyers don't surface that distinction unless you ask. They review for legality and obvious red flags. They don't model out the downstream equity math on edge cases. They don't flag provisions that are standard but quietly damaging at the wrong valuation cap. That's on you.
After analyzing thousands of SAFE agreements, here are the five risks we see most often — the ones that survive attorney review and cost founders meaningful equity at the finish line.
1
Liquidation Preference Traps Inside "Standard" SAFEs
What it is
Most SAFEs use YC's standard template, which converts at the next priced round with no liquidation preference. But SAFEs drafted by investor counsel — or modified from the YC template — sometimes include a liquidation preference multiplier. Even a 1x non-participating preference looks harmless until you model what happens in a downside exit.
Why your lawyer misses it
A 1x liquidation preference is completely legal and not uncommon in early-stage instruments. Your attorney won't flag it as a red flag because it isn't one — in isolation. What they won't do is model what it means if your company exits at a value equal to or below the post-money cap. At that exit price, investors recoup their principal first. Founders and common shareholders split whatever's left. In a $2M exit on a $10M cap SAFE, "whatever's left" can be nothing.
On a modest exit of 1–2× invested capital, a liquidation preference can move 60–100% of proceeds away from founders. This is the silent killer of "acqui-hire" outcomes.
Look for any "liquidation preference" clause in your SAFE. YC's post-money SAFE has none — it converts pro rata with no preference. If your document has one, model three exit scenarios: at cap, below cap, and 2× cap. The math tells you what's actually at stake.
2
Pro-Rata Rights That Compound Into Blocking Power
What it is
Pro-rata rights let SAFE holders maintain their ownership percentage in future rounds. In isolation, this is standard and reasonable. The problem is accumulation: if you've issued SAFEs to 12 investors over 18 months and each has broad pro-rata rights, you now have 12 investors who collectively must be offered participation in every future round. At Series A, this can eat 30–50% of the round allocation before you've offered a single dollar to your lead investor.
Why your lawyer misses it
Any individual SAFE's pro-rata right is standard. No attorney will flag it as problematic. What they won't model is the aggregate burden when you've signed six or eight SAFEs, each with the same clause. The cumulative obligation only becomes visible when you're trying to close a priced round and your cap table is locked up.
Founders have lost Series A lead investors because the pro-rata obligations to SAFE holders left too little room. Leads don't want to fight for allocation in their own round. They walk.
Model your pro-rata obligations in aggregate across all SAFEs, not per instrument. If total pro-rata rights exceed 20–25% of anticipated future rounds, negotiate: convert to "major investor" thresholds (pro-rata only for checks above $X), or carve out rights to lead investors.
3
Anti-Dilution Gotchas at Conversion
What it is
Most SAFEs don't have anti-dilution provisions — they convert at a discount or cap without adjustment. But SAFEs issued with a valuation cap can behave like they have anti-dilution protection, depending on how the conversion formula is written. Specifically: "pre-money cap" SAFEs vs. "post-money cap" SAFEs produce dramatically different conversion prices if you've raised multiple SAFEs, and founders frequently don't model this until they're staring at a capitalization table that's 40% diluted before Series A closes.
Why your lawyer misses it
This isn't anti-dilution in the legal sense — it's a structural feature of how conversion math works. Lawyers review whether the conversion clause is enforceable, not whether it's optimal for founders given the rest of the cap table. The pre/post-money distinction is almost never surfaced as a risk item in an attorney review.
YC's post-money SAFE was specifically redesigned to make dilution predictable for founders. Pre-money SAFEs issued alongside a post-money SAFE can produce confusion about the actual conversion ownership percentages — and surprises at Series A that are contractually irreversible.
Confirm whether each SAFE in your cap table is pre-money or post-money capped. Model the conversion ownership percentage for each instrument at your anticipated Series A valuation. If you're mixing pre-money and post-money SAFEs, get a cap table lawyer or a tool to model the interaction before you issue more paper.
Reading about risks is one thing. Finding them in your actual documents is another.
Upload your SAFE and get a quantitative risk score in under 5 minutes.
Check Your Terms Free →4
MFN Clause Pitfalls That Work Against You
What it is
A Most Favored Nation (MFN) clause entitles an early SAFE holder to the terms of any later SAFE you issue, if those terms are better. On the surface, this is reasonable — they took a risk early and shouldn't be disadvantaged if later investors get better terms. In practice, MFN clauses can work against founders in several ways.
Why your lawyer misses it
The MFN is legal, standard in early SAFEs, and not facially harmful. What attorneys don't model: (1) If you later issue a SAFE at a lower cap to close a difficult round, MFN triggers cascade and all prior SAFE holders are entitled to elect that lower cap. (2) Some MFN clauses include the right to elect any term — including a discount, a liquidation preference, or a pro-rata right — not just the cap. Broad MFN language quietly grants prior investors pick-and-choose rights over every future instrument you issue.
A bridge round at a lower valuation cap, intended to close quickly, can trigger MFN cascade — retroactively adjusting all prior SAFE holders to the lower cap. A $4M cap you thought was clean at your seed becomes a $2M cap on every dollar raised in a bridge.
Read the scope of your MFN clause carefully: does it apply to "any SAFE issued at a lower valuation cap" or "any SAFE with more favorable terms"? The latter is far broader. Narrow language to cap-only MFN and include a sunset provision (MFN expires at Series A, or 18 months from issuance).
5
Conversion Cap Manipulation at Priced Rounds
What it is
The valuation cap on a SAFE determines the maximum price at which the SAFE converts. A $5M cap converts at $5M regardless of whether your Series A is priced at $15M or $50M. What founders often miss: conversion doesn't always happen at the cap. Some SAFEs are written with language that allows — or even requires — conversion at a price that's further discounted from the cap if certain triggering events occur (a down round, a change of control, a new security with a lower implied valuation). This is rare but exists, and it's easy to miss in a quick legal review.
Why your lawyer misses it
The conversion formula is typically reviewed for mathematical accuracy, not for adversarial interpretation. Edge cases — what happens if your Series A is a down round from your SAFE cap? What triggers the cap vs. the discount mechanism? — are often not war-gamed explicitly.
In a down round, SAFE holders may convert at an even deeper discount than anticipated, further increasing their ownership percentage at the expense of founders and earlier common stockholders. What was modeled as 15% dilution becomes 22% — locked in contractually at the worst possible moment.
Model your conversion at multiple Series A valuations: at-cap, above-cap, and below-cap. Confirm which mechanism triggers in each scenario (cap conversion or discount conversion). Make sure the SAFE clearly states that conversion occurs at the more favorable of the cap and the discount — not the lesser.
The Bottom Line
None of these risks are exotic. They show up in standard agreements, prepared by competent attorneys, signed by sophisticated founders who thought they understood what they were signing. The issue isn't bad lawyers — it's that legal review and equity modeling are two different jobs, and most founders only get one of them done before they close.
The five risks above — liquidation preference traps, compounding pro-rata obligations, pre/post-money cap confusion, broad MFN clauses, and conversion edge cases — are consistently the highest-impact issues in SAFE agreements that look clean on the surface. They don't show up as errors. They show up as surprises at Series A, or worse, at exit.
You can model them manually if you have the time. Or you can upload your document and let Robaer surface them in minutes, with quantitative scoring on each risk vector. Either way: know what you're signing before you sign it.